How do you build a mental health and behavioral health platforms (Lyra / Spring Health) go-to-market motion in 2027?

What changes by company stage

A behavioral health platform sells a fundamentally different thing at each stage of its own maturity, and the motion has to change with it. The variable that moves is not the buyer's title — it is almost always a CHRO, VP Benefits, or Head of Total Rewards — but the *proof burden* they demand and the *network depth* you can actually deliver. Treat the company's own stage, not the prospect's size, as the primary constraint on what you can credibly promise.

At the seed/early stage, you have a thin provider network (often a single specialty: pediatric, substance use, or a therapist marketplace) and no employer outcomes data. Your entire GTM is founder-led, single-region, and evidence-starved. You cannot promise 8–15% utilization because you have never run a book of business large enough to prove it. So the stage-appropriate sale is a narrow wedge to a mid-market employer (1,000–5,000 employees) who is frustrated with their legacy EAP's 2–4% utilization and willing to pilot. ACV lands at $5K–$30K, cycles run 30–90 days, and you win on responsiveness and a specific clinical niche rather than breadth. The founder personally runs the first ten pilots, because nobody else yet knows how to translate a fuzzy "we care about mental health" mandate into a measurable engagement target.

At the growth stage, the platform has a multi-state licensed network, PHQ-9/GAD-7 outcomes across several cohorts, and one or two marquee references. Now the committee expands. The Chief Medical Officer or Director of Mental Health enters to interrogate clinical quality and provider credentialing; the CFO models per-employee economics against downstream medical-claims reduction; the CISO scrutinizes HIPAA, state mental-health-privacy statutes, and 42 CFR Part 2 for substance-use records. Deals stretch to 3–9 months and $30K–$200K ACV, and you begin needing HRIS integrations (Workday, SAP SuccessFactors, ADP, Rippling) and benefits-broker relationships to reach the buyer at all. The organization has to add a real sales function here — a founder-led motion that worked at ten logos cannot personally shepherd fifty concurrent 3–9 month cycles, and the hand-off from founder to first quota-carrying reps is where many platforms stall.

At the enterprise stage, you are selling to a 5,000–50,000+ employee employer against Lyra or Spring Health directly. The five-seat committee is fully mobilized, procurement and legal add months, and the CFO wants outcomes-based or shared-savings terms. Cycles run 9–18 months and ACV reaches $200K–$5M+. Here the platform must demonstrate global coverage, family and pediatric benefits, measurement-based care, and integration parity — the table stakes an incumbent already ships. The buyer is no longer evaluating whether digital behavioral health is worthwhile; they have already decided that, and are now choosing between you and two or three named competitors on breadth, references, and price defensibility.

The strategic error is running an enterprise motion at seed (you will burn 12 months chasing a Fortune 500 you cannot service) or a self-serve motion at enterprise (you will lose to the broker-endorsed incumbent). Match the motion to the stage, and re-tool deliberately at each transition rather than assuming the early playbook scales upward untouched.

Stage-by-stage playbook

Execute a distinct playbook per stage, and treat the transition between them as a deliberate re-tooling of pipeline, pricing, and hiring rather than a smooth continuum. Each stage has a single dominant job to be done, and spreading effort across all three at once is the most common way growth-stage revenue plateaus.

Early stage — win the wedge. Pick one underserved sub-vertical where the incumbents are weak: pediatric and family behavioral health, substance-use treatment, school-based care, or a therapist-network model. Sell direct to mid-market benefits leaders through inbound content and founder outbound. Lead with a 60-day pilot run alongside the incumbent EAP. Instrument it obsessively: utilization rate, time-to-first-appointment (target under 5–7 days versus the industry's frequent 2–3 week waits), PHQ-9/GAD-7 symptom improvement, and member CSAT. A clean pilot converts materially better than a cold proposal — the pilot is your single most powerful conversion asset. Keep the sales collateral thin and the clinical evidence thick; at this stage the buyer is taking a bet on you, and every data point you can show from a live cohort de-risks that bet more than any deck.

Growth stage — build the channel. Layer in benefits brokers (Mercer, WTW, Aon, Lockton, Gallagher, USI, HUB control a large majority of employer benefits decisions) and HRIS ecosystem integrations. Certify on Workday and SAP SuccessFactors so eligibility files, SSO, and utilization reporting flow automatically — an integration gap that forces manual eligibility uploads will quietly cap your utilization and hand the CMO seat a reason to doubt your outcomes. Add field reps who own the 3–9 month cycle and a Solutions Architect who owns pilot execution and go-live. Publish outcomes data through third-party validators so the CMO seat has independent evidence to cite internally. This is also the stage to build a repeatable pilot-to-contract playbook: standardize the 60-day instrumentation, the readout deck, and the renewal conversation so every rep runs the same motion rather than reinventing it per deal.

Enterprise stage — earn the platform seat. Bring on ex-Lyra, ex-Spring Health, or ex-Modern Health field executives who carry C-suite relationships and category credibility. Offer outcomes-based and risk-bearing pricing structures the CFO can defend. Ship the full compliance package: 42 CFR Part 2 handling, aggregated/anonymized employer reporting, SOC 2, and state-privacy conformance. Expand land-and-expand from a single division to global rollout via quarterly business reviews. At enterprise you also need a formal security and clinical review team that can survive a 5,000-employee employer's procurement gauntlet — legal redlines, vendor-risk questionnaires, and a clinical advisory board the buyer's CMO will actually respect. The motion here is less about selling and more about surviving diligence without losing the champion's momentum.

Numbers that matter at each stage

Anchor every stage to the metrics a benefits leader and CFO actually underwrite. The economics of mental and behavioral health platforms are utilization-driven — the whole model breaks if members do not engage, because a per-employee fee paid on a population that never books an appointment is the fastest way to lose a renewal.

Pricing. Per-employee-per-month lands $5–$30 PEPM depending on tier and coverage breadth; per-visit therapy and psychiatry run roughly $80–$200 per session; therapist-network models bill a small per-claim fee rather than PEPM; enterprise platform fees reach $500K–$5M+ annually for Fortune 500 populations. Avoid three-year lock-ins early — one-year terms win switchers dissatisfied with an incumbent. Structure the PEPM so that the CFO can compare it apples-to-apples against the incumbent EAP's per-employee cost, then layer the outcomes story on top; a buyer who cannot map your price to their current line item will stall in procurement.

Utilization — the make-or-break number. Legacy EAPs commonly see 2–5% engagement. Modern platforms target 8–15%, and hitting it requires active employer promotion, manager training, low-friction access, and fast time-to-appointment. If you contract to 10% and deliver 4%, renewal and any outcomes-based revenue collapse. Build employer activation into the implementation plan, not as an afterthought — a launch communications kit, manager-training sessions, and a 90-day engagement ramp with named milestones. The platforms that consistently hit double-digit utilization treat the employer's internal launch as a shared project with a mutual success plan, not a link they email once and forget.

Cycle length and ACV by stage. Early/SMB single-team: 30–90 days, $5K–$30K ACV. Mid-market (1K–25K employees): 3–9 months, $30K–$200K ACV. Enterprise: 9–18 months, $200K–$5M+ ACV. Staff and forecast against these ranges honestly; a rep hired to close mid-market in 90 days will misforecast every enterprise deal on their board, and a board that models enterprise ACV on a mid-market cycle length will perpetually miss quarter.

Efficiency and retention. Model CAC payback in the 8–20 month range, smoothed by multi-year enterprise terms and module attach (medication management, family coverage, coaching, EAP replacement). Target net revenue retention of roughly 108–120%, driven by seat growth, module attach, and multi-division expansion. Pipeline cost per qualified enterprise opportunity typically runs several thousand to low-five-figures, so field productivity and pilot conversion determine whether the model works. Gross margin sits materially below pure software because you pay a clinical network — plan for roughly 50–70% depending on how much care delivery you own versus broker to marketplace providers. Because margin is capped by the cost of care, revenue quality matters more than raw logo count: a hundred employers at 4% utilization is a worse business than sixty at 12%, both on margin and on reference strength.

Channel mix at scale. A workable blend is roughly one-quarter inbound (health-benefits media, HR communities, SEO, review sites), around 30% partner-led (HRIS ecosystem plus benefits brokers), a third outbound field to Global 2000 accounts, and small slices for conferences and existing-customer expansion. The broker channel is not optional at enterprise — standalone direct-to-employer struggles without broker endorsement, because the broker is often the first party the CHRO calls when scoping a behavioral health RFP. Invest in broker enablement (named partner managers, co-branded outcomes one-pagers, and a fast reference-request process) with the same seriousness you invest in direct field reps.

Decision framework

Use a stage-gated decision framework so you never over-invest ahead of the proof you can show. The gating question at every fork is: *do I have the network depth and outcomes evidence this buyer requires, and can I reach them through a channel they trust?*

If you lack multi-state network coverage, do not chase enterprise — you cannot service the population and a failed rollout poisons your reference base. If you have outcomes data but no broker relationships, invest there before adding field reps, because brokers gate most employer decisions. If utilization in your existing book is under 8%, fix activation and access before signing outcomes-based contracts that will punish you for the gap. And if privacy architecture (42 CFR Part 2, aggregated reporting) is not airtight, the CISO seat will veto regardless of clinical quality. Each of these is a hard gate, not a preference: a single failed enterprise rollout does more damage to a growth-stage platform's revenue trajectory than a quarter of missed pipeline, because the lost reference compounds against every future deal in that broker's book.

Applied honestly, this framework keeps a growth-stage platform from making the two classic mistakes: promising enterprise breadth it cannot deliver, and signing risk-bearing contracts before its utilization engine is real. The discipline is not glamorous, but it is what protects gross margin and reference quality as the revenue base scales. Run every large opportunity through these four gates before committing field and clinical resources, and let a "no" at any gate route the deal back to a motion you can actually win rather than forcing it forward into a rollout you cannot support.

Related questions

How is this different from selling a legacy EAP?

Legacy EAPs sold on price and box-checking with 2–5% utilization; behavioral health platforms sell on measured clinical outcomes, fast access, and 8–15% engagement. The buyer shifts from a benefits-compliance mindset to an outcomes-and-ROI mindset, which raises the proof burden but also the ACV.

Why do benefits brokers matter so much?

Brokers (Mercer, WTW, Aon, Lockton, Gallagher, USI, HUB) advise and gate a large majority of employer benefits decisions. Without broker endorsement, a standalone platform rarely reaches the CHRO's shortlist, so channel co-sell is a structural requirement rather than a growth-hack at the mid-market and enterprise tiers.

What outcomes should the pilot measure?

Utilization rate, time-to-first-appointment, validated symptom improvement (PHQ-9 for depression, GAD-7 for anxiety), and member CSAT. These four map directly to the CHRO's engagement concern, the CMO's clinical-quality concern, and the CFO's ROI concern — the seats that decide the deal.

How do you compete against Lyra and Spring Health directly?

You rarely out-incumbent the leaders on breadth. Win a specific wedge — pediatric/family, substance use, school-based, therapist-network, or a niche population — where their generalist network is thin, then expand adjacency by adjacency once you own the beachhead.

What breaks a behavioral health GTM most often?

The provider-network cold-start (credentialing a multi-state network takes many months and burns cash) and the utilization gap (delivering 3–5% against a promised 8–15%). Both are solvable with activation investment and staged network build, but ignoring either sinks renewals.

FAQ

What's the right opening price for a mid-market employer? Lead with per-employee-per-month in the $5–$30 range depending on coverage tier, plus per-visit fees for therapy and psychiatry. Favor a one-year term over a three-year lock-in — switchers dissatisfied with an incumbent EAP are far easier to close on annual commitments they can exit.

How long should the pilot run? Sixty days on a single employer of roughly 5,000–50,000 members, run alongside the incumbent. That window is long enough to measure utilization ramp, time-to-first-appointment, early PHQ-9/GAD-7 movement, and CSAT, while short enough to keep the buying committee engaged and the champion motivated.

What CAC payback should I target? Roughly 8–20 months. Longer paybacks are tolerable at enterprise because multi-year terms and module attach smooth the curve, but early-stage motions should stay near the bottom of that range or the burn outpaces the network build.

What net revenue retention is healthy? Around 108–120%. Expansion comes from added seats, module attach (medication management, family and pediatric coverage, coaching, full EAP replacement), and multi-division rollout. If NRR sits below ~105%, examine utilization and activation before adding more logos.

How do I handle privacy and compliance? Architect for HIPAA, state mental-health-privacy statutes, and 42 CFR Part 2 for substance-use records from day one. Employer reporting must be aggregated and anonymized — individual utilization data cannot flow back to the employer. The CISO or Director of Privacy holds an effective veto, so treat this as a gating requirement, not a late-stage checkbox.

Which sub-verticals are most underserved heading into 2027? Pediatric and family behavioral health, substance-use treatment, school-based care, employer EAP replacement, and niche populations (women's, veteran-specific, LGBTQ+). These are where generalist incumbents run thin networks, giving a focused platform a defensible wedge before broadening.

Sources

• Business Group on Health — employer health and mental health benefits research: https://www.businessgrouponhealth.org
• KFF (Kaiser Family Foundation) — mental health and health-coverage tracking: https://www.kff.org
• NAMI (National Alliance on Mental Illness) — state of mental health data: https://www.nami.org
• SAMHSA — behavioral health data and 42 CFR Part 2 guidance: https://www.samhsa.gov
• American Psychological Association — workplace mental health research: https://www.apa.org
• Lyra Health — enterprise behavioral health platform and customer benchmarks: https://www.lyrahealth.com
• Spring Health — enterprise mental health platform: https://www.springhealth.com
• Forrester — behavioral health and benefits market research: https://www.forrester.com
• Gartner — digital health and platform market research: https://www.gartner.com

Related on PULSE

• [How do you build a population health platforms (Arcadia / Innovaccer) go-to-market motion in 2027?](/knowledge/gp0114)
• [How do you build a caregiving and home health software (CareAcademy / WellSky) go-to-market motion in 2027?](/knowledge/gp0111)
• [How do you build an EHS (environment health safety) software go-to-market motion in 2027?](/knowledge/gp0045)
• [GTM Playbook for Home Health Care Agencies in 2027](/knowledge/gp0339)
• [How do you build a biotech research platforms (Benchling / Schrödinger) go-to-market motion in 2027?](/knowledge/gp0118)